18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
This study intends to use a prospective, observational, self-controlled, multi-center study design to evaluate the feasibility and diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/MRI imaging for the evaluation of systemic fibrosis in MF patients based on the results of bone marrow pathological biopsy, and to ana
| Condition(s) | Myelofibrosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study intends to use a prospective, observational, self-controlled, multi-center study design to evaluate the feasibility and diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/MRI imaging for the evaluation of systemic fibrosis in MF patients based on the results of bone marrow pathological biopsy, and to analyze the relationship between imaging results and clinical prognosis. |
| Who can participate | Inclusion Criteria: * Patients with primary myelofibrosis or myelofibrosis secondary to myeloid tumors were diagnosed according to the diagnostic criteria of who 2022. * Stable vital signs, ECOG score ≥ 2 points, tolerate and cooperate to complete 18F-FDG PET/CT and 18F-FAPI PET/MRI examination. * The interval between imaging ,hematologic, cytogenetic and pathology was \< 2 weeks. * Willing to accept 18F-FDG PET/CT and 18F-FAPI PET/MRI , sign the informed consent. Exclusion Criteria: * Inability or unwillingness to provide informed consent. * Other malignancies, autoimmune diseases, or chronic active infections were diagnosed within 1 year before the diagnosis of myelofibrosis. * Current infection was present within 1 week before PET examination. * Pregnant or lactation. * Unable to follow |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | First Affiliated Hospital of Zhejiang University |
| Locations | Hangzhou, Zhejiang, China |
| Start date | 2023-11-21 |
| NCT ID | NCT06164561 |
| Official listing | https://clinicaltrials.gov/study/NCT06164561 |